Request for Information (RFI): Patient and Family Needs and Requirements to be Addressed by the Small Business Programs of the National Institute on Drug Abuse (NIDA)

Notice Number: NOT-DA-17-049

Key Dates
Release Date: July 18, 2017
Expiration Date: New Date : September 1, 2017

Related Announcements


Issued by
National Institute on Drug Abuse (NIDA)


NIDA is looking for feedback from patients and families who are affected by drug abuse and addiction. This RFI is published to explore the needs of patients and families which could be addressed by the NIDA’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer Research (STTR) Programs.


NIDA is the Federal Government's lead agency for supporting scientific research on drug abuse and addiction. NIDA's mission is to advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health. NIDA-supported science addresses the most fundamental and essential questions about drug abuse, which range from the molecule to managed care and from DNA to community outreach research.

NIDA, a part of the NIH, is required by statute (SBIR/STTR Reauthorization Act of 2011) to reserve a portion of its annual budget for projects under the SBIR and STTR programs. The SBIR and STTR programs are one of the largest sources of early-stage capital for innovative small companies in the United States. These programs allow small businesses to engage in research and development (R&D) that has a strong potential for commercialization. Commercialization is the process of introducing a new and valuable product or service into the marketplace.

NIDA is interested to use SBIR and STTR programs as a tool to develop and commercialize novel technologies and services to address the immediate needs of patients and families who are affected by drug abuse and addiction. 

Request for Information

Public comment is sought on all topics in regards to what challenges patients and families are facing and more specifically what type of technology and methodology NIDA may develop. Feedback may include, but is not limited to:

  • The significant unaddressed needs of patients and their families suffering from addiction
  • The effectiveness and usefulness of current programs and products at helping people with addiction
  • The accessibility of current treatment, prevention, and education programs
  • The type of help that is currently unavailable
  • The questions not being asked or addressed by scientists to help people struggling with addiction

Submitting a Response

We are grateful for your interest and help. All responses must be submitted via email to  Please include the Notice number NOT-DA-17-049 in the subject line. 

Response to this RFI is voluntary. Responders are free to address any or all of the categories listed above. The submitted information will be reviewed by NIDA staff. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. This request is for information and planning purposes only and should not be construed as a solicitation or as an obligation on the part of the Federal Government. The NIH does not intend to make any awards based on responses to this RFI or to otherwise pay for the preparation of any information submitted or for the Government's use of such information. Responses to the RFI may be reflected in future funding opportunity announcements. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). The information provided will be analyzed and may appear in reports. No proprietary, classified, confidential, or sensitive information should be included in your response. 


Please direct all inquiries to:

Elena Koustova, PhD, MBA
National Institute on Drug Abuse (NIDA)
Telephone: 301-496-8768